Edwards Lifesciences (NYSE:EW) PT Raised to $255.00 at Raymond James

Edwards Lifesciences (NYSE:EW) had its target price boosted by analysts at Raymond James from $250.00 to $255.00 in a report issued on Thursday, AnalystRatings.com reports. The firm currently has an “outperform” rating on the medical research company’s stock. Raymond James’ price target would indicate a potential upside of 11.42% from the company’s previous close.

EW has been the subject of a number of other research reports. Bank of America reaffirmed a “buy” rating and set a $225.00 price objective (up previously from $215.00) on shares of Edwards Lifesciences in a research report on Wednesday, July 24th. Cowen reaffirmed a “positive” rating and set a $265.00 price objective (up previously from $250.00) on shares of Edwards Lifesciences in a research report on Thursday. Credit Suisse Group raised their price objective on Edwards Lifesciences from $226.00 to $261.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. ValuEngine lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Royal Bank of Canada raised their price objective on Edwards Lifesciences from $217.00 to $250.00 and gave the company an “outperform” rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $237.89.

EW stock opened at $228.86 on Thursday. Edwards Lifesciences has a twelve month low of $136.44 and a twelve month high of $238.37. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18. The firm has a market cap of $46.83 billion, a PE ratio of 48.69, a price-to-earnings-growth ratio of 2.84 and a beta of 0.84. The business has a 50 day moving average of $222.41 and a 200 day moving average of $199.73.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 33.36% and a net margin of 18.64%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the company earned $1.07 EPS. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. On average, research analysts expect that Edwards Lifesciences will post 5.33 earnings per share for the current fiscal year.

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 21,000 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $211.92, for a total transaction of $4,450,320.00. Following the sale, the vice president now directly owns 41,713 shares in the company, valued at approximately $8,839,818.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Huimin Wang sold 4,650 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $211.54, for a total value of $983,661.00. Following the sale, the vice president now owns 36,898 shares in the company, valued at $7,805,402.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 137,253 shares of company stock worth $29,736,031. Company insiders own 1.63% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of EW. Jennison Associates LLC boosted its stake in shares of Edwards Lifesciences by 4.8% in the 2nd quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after buying an additional 275,182 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 8,278.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after buying an additional 3,904,405 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Edwards Lifesciences by 2.1% in the 2nd quarter. Northern Trust Corp now owns 2,422,599 shares of the medical research company’s stock worth $447,551,000 after buying an additional 48,931 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Edwards Lifesciences by 7.2% in the 2nd quarter. Royal Bank of Canada now owns 1,650,840 shares of the medical research company’s stock worth $304,976,000 after buying an additional 110,497 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its stake in shares of Edwards Lifesciences by 9.7% in the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 1,314,685 shares of the medical research company’s stock worth $242,876,000 after buying an additional 115,881 shares during the last quarter. Institutional investors and hedge funds own 81.75% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: Analyzing a company’s cash flow statement

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.